A retrospective 5-year review of rubella in South Africa prior to the introduction of a rubella-containing vaccine
South Africa has yet to introduce a rubella-containing vaccine (RCV) into its Expanded Programme on Immunisation (EPI). Here we evaluated the incidence of laboratory-confirmed rubella and congenital rubella syndrome (CRS) cases over the years 2015 to 2019, to document the epidemiology of rubella and CRS within South Africa prior to a RCV introduction. This retrospective study evaluated the number of laboratory-confirmed rubella cases reported through the national febrile rash surveillance system. A positive test for rubella immunoglobulin M (IgM) antibodies was considered a confirmed rubella case. For CRS cases, we reported laboratory-confirmed CRS cases collected from 28 sentinel-sites from all nine provinces of South Africa. From 2015-2019, 19 773 serum samples were tested for rubella IgM antibodies, 6 643 (33.6%) were confirmed rubella cases. Rubella was seasonal, with peaks in spring (September to November). Case numbers were similar between males (n = 3 239; 50.1%) and females (n = 3 232; 49.9%). The highest burden of cases occurred in 2017 (n = 2 526; 38%). The median age was 5 years (IQR: 3-7 years). Importantly, of females with rubella, 5.0% (161 of 3 232) of the cases were among women of reproductive age (15-44 years). A total of 62 CRS cases were reported, the mortality rate was 12.9% (n = 8), and the most common birth defect was congenital heart disease. In conclusion, rubella is endemic in South Africa. Children below the age of 10 years were the most affected, however, rubella was also reported among women of reproductive age. The baseline data represented here provides insight into the burden of rubella and CRS in South Africa prior to the introduction of a RCV, and can enable planning of RCV introduction into the South African EPI.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
PloS one - 17(2022), 5 vom: 18., Seite e0265870 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hong, Heather [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Immunoglobulin M |
|---|
| Anmerkungen: |
Date Completed 09.05.2022 Date Revised 12.01.2023 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.1371/journal.pone.0265870 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340406445 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340406445 | ||
| 003 | DE-627 | ||
| 005 | 20231226005138.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1371/journal.pone.0265870 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1134.xml |
| 035 | |a (DE-627)NLM340406445 | ||
| 035 | |a (NLM)35512030 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hong, Heather |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A retrospective 5-year review of rubella in South Africa prior to the introduction of a rubella-containing vaccine |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.05.2022 | ||
| 500 | |a Date Revised 12.01.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a South Africa has yet to introduce a rubella-containing vaccine (RCV) into its Expanded Programme on Immunisation (EPI). Here we evaluated the incidence of laboratory-confirmed rubella and congenital rubella syndrome (CRS) cases over the years 2015 to 2019, to document the epidemiology of rubella and CRS within South Africa prior to a RCV introduction. This retrospective study evaluated the number of laboratory-confirmed rubella cases reported through the national febrile rash surveillance system. A positive test for rubella immunoglobulin M (IgM) antibodies was considered a confirmed rubella case. For CRS cases, we reported laboratory-confirmed CRS cases collected from 28 sentinel-sites from all nine provinces of South Africa. From 2015-2019, 19 773 serum samples were tested for rubella IgM antibodies, 6 643 (33.6%) were confirmed rubella cases. Rubella was seasonal, with peaks in spring (September to November). Case numbers were similar between males (n = 3 239; 50.1%) and females (n = 3 232; 49.9%). The highest burden of cases occurred in 2017 (n = 2 526; 38%). The median age was 5 years (IQR: 3-7 years). Importantly, of females with rubella, 5.0% (161 of 3 232) of the cases were among women of reproductive age (15-44 years). A total of 62 CRS cases were reported, the mortality rate was 12.9% (n = 8), and the most common birth defect was congenital heart disease. In conclusion, rubella is endemic in South Africa. Children below the age of 10 years were the most affected, however, rubella was also reported among women of reproductive age. The baseline data represented here provides insight into the burden of rubella and CRS in South Africa prior to the introduction of a RCV, and can enable planning of RCV introduction into the South African EPI | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Immunoglobulin M |2 NLM | |
| 650 | 7 | |a Rubella Vaccine |2 NLM | |
| 700 | 1 | |a Malfeld, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a Smit, Sheilagh |e verfasserin |4 aut | |
| 700 | 1 | |a Makhathini, Lillian |e verfasserin |4 aut | |
| 700 | 1 | |a Fortuin, Mirriam |e verfasserin |4 aut | |
| 700 | 1 | |a Motsamai, Tshepo |e verfasserin |4 aut | |
| 700 | 1 | |a Tselana, Dipolelo |e verfasserin |4 aut | |
| 700 | 1 | |a Manamela, Morubula Jack |e verfasserin |4 aut | |
| 700 | 1 | |a Motaze, Nkengafac Villyen |e verfasserin |4 aut | |
| 700 | 1 | |a Ntshoe, Genevie |e verfasserin |4 aut | |
| 700 | 1 | |a Kamupira, Mercy |e verfasserin |4 aut | |
| 700 | 1 | |a Khosa-Lesola, Ester |e verfasserin |4 aut | |
| 700 | 1 | |a Mokoena, Sibongile |e verfasserin |4 aut | |
| 700 | 1 | |a Buthelezi, Thulasizwe |e verfasserin |4 aut | |
| 700 | 1 | |a Maseti, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Suchard, Melinda |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t PloS one |d 2006 |g 17(2022), 5 vom: 18., Seite e0265870 |w (DE-627)NLM167327399 |x 1932-6203 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2022 |g number:5 |g day:18 |g pages:e0265870 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1371/journal.pone.0265870 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2022 |e 5 |b 18 |h e0265870 | ||